GlassScriptPhysician profile
Jodie D Harrison
NPI 1063061950
$11,866.10
in general payments reported to CMS, 2019-2025
61 companies · $2,414 in 2025
The $2,414 reported for 2025 was more than what 95% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,409 · 2022: $2,597 · 2023: $3,336 · 2024: $2,110 · 2025: $2,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,992 · Consulting Fee: $1,155 · Education: $474 · Travel and Lodging: $239.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,991.81 |
| Consulting Fee | $1,155.00 |
| Education | $474.30 |
| Travel and Lodging | $238.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,230.55 | 2021-2025 | Jakafi, Monjuvi |
| Janssen Biotech, INC. | $767.72 | 2021-2025 | Darzalex, Erleada, Akeega |
| E.R. Squibb & Sons, L.L.C. | $680.86 | 2021-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $523.60 | 2021-2025 | Lynparza, Enhertu, Imfinzi |
| Merck Sharp & Dohme LLC | $492.96 | 2022-2025 | Keytruda, Reblozyl, Lynparza |
| Astellas Pharma Global Development | $442.55 | 2024-2025 | Padcev, Xtandi |
| Gilead Sciences, INC. | $436.73 | 2021-2025 | Trodelvy |
| Adaptive Biotechnologies Corporation | $385.92 | 2024-2025 | Clonoseq |
| Astellas Pharma US INC | $372.03 | 2022-2025 | Padcev, Vyloy, Xtandi |
| Novartis Pharmaceuticals Corporation | $357.17 | 2022-2025 | |
| Stemline Therapeutics INC. | $290.52 | 2023-2025 | Orserdu |
| Seagen INC. | $287.04 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $265.98 | 2021-2025 | |
| Abbvie INC. | $251.99 | 2021-2025 | |
| Genentech USA, INC. | $242.14 | 2021-2025 | Venclexta, Polivy, Tecentriq Hybreza |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodie Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.